Andrew T Huang1, Chad Tang2, Diana Bell3, Murat Yener1, Luis Izquierdo1, Steven J Frank2, Adel K El-Naggar3, Ehab Y Hanna1, Randal S Weber1, Michael E Kupferman4. 1. Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States. 2. Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States. 3. Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States. 4. Department of Head and Neck Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States. Electronic address: MEKupfer@mdanderson.org.
Abstract
OBJECTIVES: We aimed to characterize prognostic factors and outcomes in adenocarcinomas of the salivary glands. MATERIALS AND METHODS: Patients were identified and retrospectively reviewed for clinical and pathologic tumor characteristics. Low and high grade adenocarcinoma histologies were separated and analyzed. Treatment regimens and patient-related outcomes were recorded and measured. RESULTS: A total of 51 adenocarcinomas of the salivary glands were reviewed. The most common locations of disease were the superficial lobe of the parotid gland, followed by the deep lobe. Five-year overall and disease free survival rates were 43% and 37%. Univariate analysis identified the following as negative prognostic factors: symptoms of a fixed mass or rapid growth, advanced tumor or nodal stage, and perineural or lymphovascular invasion. Facial nerve paralysis was not found to be a significant prognostic variable. Multivariate analysis confirmed the independent negative prognostic importance of the following characteristics: presentation with a fixed mass or rapid growth, diagnosis of adenocarcinoma not otherwise specified, and positive surgical margins. CONCLUSIONS: Our results identify several important prognostic factors associated with overall survival in adenocarcinoma of the salivary glands. These prognostic variables encompass symptoms on presentation, clinical and pathologic tumor stage characteristics, and treatment-related factors; all of which are important in patient counseling and may provide impetus for determining treatment escalation.
OBJECTIVES: We aimed to characterize prognostic factors and outcomes in adenocarcinomas of the salivary glands. MATERIALS AND METHODS:Patients were identified and retrospectively reviewed for clinical and pathologic tumor characteristics. Low and high grade adenocarcinoma histologies were separated and analyzed. Treatment regimens and patient-related outcomes were recorded and measured. RESULTS: A total of 51 adenocarcinomas of the salivary glands were reviewed. The most common locations of disease were the superficial lobe of the parotid gland, followed by the deep lobe. Five-year overall and disease free survival rates were 43% and 37%. Univariate analysis identified the following as negative prognostic factors: symptoms of a fixed mass or rapid growth, advanced tumor or nodal stage, and perineural or lymphovascular invasion. Facial nerve paralysis was not found to be a significant prognostic variable. Multivariate analysis confirmed the independent negative prognostic importance of the following characteristics: presentation with a fixed mass or rapid growth, diagnosis of adenocarcinoma not otherwise specified, and positive surgical margins. CONCLUSIONS: Our results identify several important prognostic factors associated with overall survival in adenocarcinoma of the salivary glands. These prognostic variables encompass symptoms on presentation, clinical and pathologic tumor stage characteristics, and treatment-related factors; all of which are important in patient counseling and may provide impetus for determining treatment escalation.
Authors: Diane Wenhua Chen; Jan S Lewin; Li Xu; Stephen Y Lai; G Brandon Gunn; Clifton David Fuller; Abdallah S R Mohamed; Aasheesh Kanwar; Erich M Sturgis; Katherine A Hutcheson Journal: Otolaryngol Head Neck Surg Date: 2016-10-03 Impact factor: 3.497
Authors: Oliver Bissinger; Carolin Götz; Andreas Kolk; Henning A Bier; Abbas Agaimy; Henning Frenzel; Sven Perner; Julika Ribbat-Idel; Klaus Dietrich Wolff; Wilko Weichert; Caroline Mogler Journal: Rare Tumors Date: 2017-10-03
Authors: Michał Żurek; Kamil Jasak; Karolina Jaros; Piotr Daniel; Kazimierz Niemczyk; Anna Rzepakowska Journal: Int J Environ Res Public Health Date: 2022-08-18 Impact factor: 4.614